SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending after its annual shareholder meeting, where a controversial vote to authorize 50 billion shares reportedly passed, alongside news of a $200 million equity investment in Mr. Beast's Beast Industries. The community is sharply divided, with many expressing concern over potential dilution and questioning the strategic value of the Mr. Beast deal, while others see it as a smart move for mainstream exposure, all against a backdrop of skepticism regarding CEO Tom Lee's credibility.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following reports of robust early demand for its recently launched oral Wegovy pill, which is amplified by a regulatory delay for a key competitor's oral obesity treatment. This development gives Novo Nordisk a significant first-mover advantage in the burgeoning oral GLP-1 market, driving community discussion around the drug's "game-changing" potential and the company's strong growth prospects.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

The upcoming Investor Day for Ondas Holdings is generating significant buzz, with the community highly anticipating potential announcements regarding a major contract, updated 2026 financial outlook, and a rumored spin-off of its drone division, following a substantial $1 billion capital raise. Investors are keenly watching how this capital and strategic government tenders will impact the company's trajectory, fueling fervent debate between expectations of significant upside and concerns over market manipulation and "sell the news" events. Amidst geopolitical tensions highlighting demand for drone and defense technologies, discussions center on whether Ondas Autonomous Systems can deliver transformative news to solidify its position in the rapidly expanding sector.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending after being selected as an awardee for a significant defense contract, validating its innovative direct-to-smartphone satellite technology for both civilian and military applications. The community is actively celebrating the stock's recent surge past a key psychological price level, fueling widespread discussion about a potential short squeeze and its long-term disruptive potential in global telecommunications, despite ongoing debates about its valuation as a pre-revenue company.

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Regentis Biomaterials Ltd.

Regentis Biomaterials

Regentis Biomaterials ($RGNT) is gaining significant attention due to its extremely low public float and a recently secured U.S. patent for its GelrinC liquid formulation, which many believe was initially overlooked. The community is actively discussing the stock's potential for a strong upward movement, driven by its limited tradable shares and insider lock-up, generating anticipation for increased volume and price action for this recent IPO.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings (SPHL) is trending after a massive surge, driven by news of its international expansion into solar-ready homes in Singapore. The community is actively discussing its low-float status and short-squeeze potential, drawing comparisons to other recent parabolic movers, with some traders reporting brokerage limitations on buying.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is experiencing significant market attention following its recent reverse stock split, which drastically reduced its tradable share float. This has ignited community discussion positioning it as a speculative low-float play, with many drawing comparisons to other stocks that have seen explosive short squeezes. Traders are keenly watching its high volatility and the potential for rapid price movements should momentum and volume persist.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is seeing a surge in attention following multiple analyst upgrades and its established position as a critical national security space partner through major government defense contracts. The community is actively bullish, celebrating impressive gains and eagerly anticipating milestones like the Neutron rocket's maiden flight, even amidst ongoing discussions about its valuation in a rapidly expanding sector.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to robust Phase 2 data for its obesity drug VK2735 and heightened M&A speculation following Novo Nordisk's CEO expressing openness to multi-billion dollar acquisitions in the weight-loss sector. The community is actively debating VKTX's 

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending due to recent announcements of strategic partnerships with crypto.com/us and lines.com, positioning the company to enter the rapidly expanding prediction markets space. The community is actively debating the stock's potential for significant upside, drawing comparisons to other high-volatility runners and fueling discussions around its low float and a potential short squeeze, amidst warnings about future offerings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The U.K. medicines regulator stated that the maximum dose of 7.2 mg of Wegovy only applies to adult patients with a Body Mass Index (BMI) of 30kg/m² or higher.</li><li>As part of the approval, the regulator said that the drug is to be administered as three injections of 2.4 mg each, per week.</li><li>The approval is not applicable to patients with a BMI below 30kg/m² who use Wegovy for weight management, or to those who use the drug to reduce the risk of serious heart problems.</li></ul>Novo Nordisk AS (NVO) shares were up nearly 6% in Friday’s pre-market trade amid a new development in the company’s miracle weight loss drug, Wegovy.The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> was in the ‘bullish’ territory, with the stock being the top-trending ticker on the platform at the time of writing.<h2 class="st-heading-2">What Is The Wegovy Approval About?</h2>The U.K. medicines regulator stated that the maximum dose of 7.2 mg of Wegovy only applies to adult patients with a Body Mass Index (BMI) of 30kg/m² or higher.As part of the approval, the regulator said that the drug is to be administered as three injections of 2.4 mg each, per week.The approval is not applicable to patients with a BMI below 30kg/m² who use Wegovy for weight management, or to those who use the drug to reduce the risk of serious heart problems.The regulator also noted that patients who are starting Wegovy will have to begin with the 0.25 mg dose per week. Subsequently, with advice from a prescribed health professional, the dose can be increased to 7.2 mg per week after using the drug for a minimum of four weeks.<h2 class="st-heading-2">Boost From Wegovy Pill</h2>Earlier this month, Novo&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">announced</a> that patients in the U.S. can get the oral Wegovy pill starting at $149 a month.The company stated on its website that the 1.5 mg and 4 mg doses of Wegovy will be available to self-paying customers at these prices beginning January 5. However, the cost of the 4 mg dose will rise to $199 a month from April 15, 2026.Since the announcement, Novo shares are up nearly 4%. According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-13/novo-s-ceo-is-ready-to-go-very-big-in-hunt-for-obesity-deals">report</a>, the company is also said to be back on the hunt for obesity deals after losing out on Metsera Inc. to rival Pfizer Inc. (PFE) last year.<h2 class="st-heading-2">How Did Stocktwits Users React</h2>Retail users on Stocktwits were bullish about Novo, with message volumes soaring nearly 50% over the last 24 hours.One bullish Stocktwits user believes that Novo has a “monopoly market” over the next three months.<stembedurl>https://stocktwits.com/kungfukenny___/message/642018122</stembedurl>However, one user expressed their dilemma, wondering whether the Greenland dispute could lead to a tariff increase on Denmark.<stembedurl>https://stocktwits.com/Ceri78/message/641994914</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is up 12% year-to-date, but down 31% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-loses-bid-fast-track-warner-bros-suit/cmU188XR4JP">Paramount Reportedly Loses Bid To Fast-Track Warner Bros Suit: PSKY Stock Edges Lower</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wegovy brand slimming syringes are sold in the Achat pharmacy in Mitte. Photo: Jens Kalaene/dpa (Photo by Jens Kalaene/picture alliance via Getty Images)

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares?

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

Equity

MGO One Seven LLC Has $1.39 Million Holdings in Novo Nordisk A/S $NVO

MGO One Seven LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 50.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities...

Novo Nordisk A/S (NYSE:NVO) Trading Down 3.1% - Here's What Happened

Novo Nordisk A/S (NYSE:NVO) Shares Down 3.1% - Should You Sell...

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit

Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.read more...

Top Pharmaceutical Stocks To Research - January 15th

Eli Lilly and Company, Novo Nordisk A/S, AbbVie, Pfizer, AstraZeneca, Abbott Laboratories, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Best Medical Stocks To Keep An Eye On - January 15th

Eli Lilly and Company, Penumbra, Boston Scientific, UnitedHealth Group, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...

How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?

Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.

Eagle Global Advisors LLC Trims Stake in Novo Nordisk A/S $NVO

Eagle Global Advisors LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.7% in the third quarter, according to the company in its most recent filing with the Securities...

<ul class="summary-bullets"><li>AbbVie CEO said that the company is now looking at candidates that provide sustained weight loss.&nbsp;</li><li>The obesity drug market is currently dominated by GLP-1 drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Ozempic.</li></ul>AbbVie (ABBV) chief executive officer Roopal Thakkar said on Wednesday that the company is looking to expand its obesity portfolio with candidates that help provide sustained weight loss.The obesity drug market is currently dominated by GLP-1 drugs such as Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Ozempic.Thakkar said at the annual JP Morgan Healthcare conference that key for AbbVie is tolerability and durability of weight loss for patients that tend to “cycle off of these first-gen therapies.”“Some of our data shows that only 30% or so patients are still taking these therapies after a year. So that's still, I would say, a critical aspect of our business development and licensing strategy,” Thakkar added.<h2 class="st-heading-2">Current Pipeline</h2>AbbVie already has a long-acting amylin analog for the treatment of obesity in its pipeline. A long-acting amylin analog is a drug designed to mimic the natural hormone amylin, which signals fullness and slows digestion, used for weight management in obesity and type 2 diabetes.AbbVie licensed the drug from Gubra A/S in March 2025, marking its entry into the obesity segment. The drug is currently in early stage trials."We have the longer acting amylin. We like the tolerability profile of that mechanism, but we are interested in building that out further," Thakkar said on Wednesday.AbbVie’s chief commercial officer Jeff Stewart also noted that the company wants to play in the “super dynamic” obesity market.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ABBV stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that AbbVie could become a big contender to Lilly with the right assets.<stembedurl>https://www.stocktwits.com/biolover/message/641825158</stembedurl><a href="https://stocktwits.com/symbol/ABBV">ABBV stock</a> gained 26% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-names-new-permanent-cfo-amid-warner-bros-acquisition-attempts/cmULschR47E">Paramount Names New Permanent CFO Amid Warner Bros Acquisition Attempts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Abbvie Pharma logo seen on screen in the background with pills and a medical vial with syringe, seen in this photo illustration, on 14 August 2023 in Brussels, Belgium. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly 

AbbVie already has a long acting amylin analog for the treatment of obesity in its pipeline.

Novo Nordisk A/S (NYSE:NVO) Trading Down 1.3% - Here's Why

Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.3% - Time to Sell...

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

Excitement is high over the new oral Wegovy pill, especially with reported record-high initial sales data and competitor delays creating a significant market advantage.

Controversy surrounds the CEO's recent comments about future headwinds and acquisitions, with many users blaming his remarks for killing the stock's momentum.

Traders are baffled by the stock's drop despite a flurry of positive news, leading to speculation of market manipulation and strong conviction to 'buy the dip.'

Heavy speculation surrounds potential acquisitions or partnerships as the CEO indicates a willingness to expand the obesity drug portfolio through strategic deals.

Unusual discussions are emerging regarding potential geopolitical tensions between the US and Denmark over Greenland, with some users citing it as a risk factor for the stock.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVO News

NVONovo Nordisk A/S